Krystal Biotech Inc Stock News

Krystal Biotech Inc (NASDAQ: KRYS ) shares have potential to nearly double from current levels, according to an analyst at BofA Securities. The Krystal Biotech Analyst: Geoff Meacham initiated coverage of Krystal Biotech shares with a Buy rating and a $110 price target. The Krystal Biotech Thesis: Krystal Biotech, a clinical-stage biotech, is developing differentiated HSV-based gene therapies for inherited dermatological and respiratory diseases, Meacham said in a note. Krystal differentiates itself due to its ability to package large transgenes and re-dose their gene therapies in a transient manner, which significantly increases the breadth of potential applications, the analyst said. Nominated therapeutic areas include cystic fibrosis, Full story available on Benzinga.com

Krystal Biotech Inc (NASDAQ:KRYS) shares have potential to nearly double from current levels, according to an analyst at BofA Securities. The Krystal Biotech Analyst: Geoff Meacham initiated coverag

PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing

Vontobel Holding Ltd. decreased its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,398 shares of the companys stock after selling 2,749 shares during the quarter. Vontobel Holding Ltd. owned approximately 0.10% [] The post Vontobel Holding Ltd. Sells 2,749 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) appeared first on ETF Daily News .

This company has made quite a lot of noise recently.

This company has made quite a lot of noise recently.

Krystal Biotech, Inc. (NASDAQ:KRYS) has earned an average rating of Buy from the six brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have updated []

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.

On Nov 29, KRYS reported positive topline results from their pivotal phase 3 trial of "VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa (DEB).

The company had a positive phase 3 trial for its therapy to fight a rare genetic skin disease.

The company had a positive phase 3 trial for its therapy to fight a rare genetic skin disease.

The company had a positive phase 3 trial for its therapy to fight a rare genetic skin disease.

In last trading session, Krystal Biotech Inc. (NASDAQ:KRYS) saw 2.63 million shares changing hands with its beta currently measuring 1.07. Companys recent per share price level of $69.68 trading at -$10.87 or -13.49% at ring of the bell on the day assigns it a market valuation of $1.48B. That closing price of KRYSs stock is Krystal Biotech Inc. (NASDAQ:KRYS) Stock Boosted 16.13% So Far In 2021, What Analysts Expect Next? Read More »

A public offering is weighing on the biotech's shares today.

A public offering is weighing on the biotech's shares today.